U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 38

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated October 7, 2011,
1. Beebe Medical Center	3. License number 07-17792-01 is amended in its entirety to read as follows:
2. 424 Savannah Road Lewes, Delaware 19958	4. Expiration date January 31, 2014
	5. Docket No. 03013331 Reference No. 07-31145-01

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1000 millicuries
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources as specified in Condition 12	D. 1 curie
E. Gadolinium-153 permitted by 10 CFR 35.500	E. Sealed Source (IPL Model NES 8497)	E. 300 millicuries per source and 1 curie total

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 424 Savannah Road, Lewes, Delaware.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-17792-01

Docket or Reference Number
03013331

Amendment No. 38

B. Licensed material in Item 6.B. may be used or stored at the licensee's facilities located at the Beebe Health Campus, Bookhammer Outpatient Center, 18941 John J. Williams Highway (Route 24), Rehoboth Beach, Delaware.

C. Licensed material in Item 6.D. may be used or stored at the licensee's facilities located at the Beebe Outpatient Surgery Center, 18941 John J. Williams Highway (Route 24), Rehoboth Beach, Delaware.

11. The Radiation Safety Officer for this license is Suzanne Krueger-Schmidt.

12. Sealed sources permitted by this license include:

Isotope	Source Model Number	Maximum Activity Per Source
I-125	Medi-Physics, Inc. (d/b/a GE Healthcare) Model 6711	270 millicuries
I-125	Medi-Physics, Inc. (d/b/a GE Healthcare) Model 6733	72 millicuries
I-125	North American Scientific, Inc. Model MED3631	25 millicuries
I-125	Best Medical International, Inc. Model 2300 Series	110 millicuries
I-125	BEBIG Model I25.SO6	40 millicuries
I-125	Core Oncology, Inc. (formerly Mills Biopharmaceuticals, LLC) Model I-125SL	1 millicurie
I-125	Core Oncology, Inc. (formerly Mills Biopharmaceuticals, LLC) Model I-125SH	150 millicuries
I-125	IsoAid, LLC Model IAI-125A	10 millicuries
I-125	Bard Brachytherapy, Inc. Model STM1251	15 millicuries
I-125	Draxis Specialty Pharmaceuticals, Inc. (formerly Draximage, Inc.) Model LS-1	75 millicuries
I-125	Implant Sciences Corporation, Model 3500	7.5 millicuries
I-125	IsoStar Texas, Inc. (d/b/a Imagyn Medical Technologies) Model IS-12501	10 millicuries

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-17792-01

Docket or Reference Number
03013331

Amendment No. 38

I-125	International Brachytherapy, Inc. Model 1251L	6.5 millicuries
I-125	Syncor Pharmaceuticals, Inc. Model BT-125-1	6 millicuries
I-125	Amersham/Medi-Physics, Inc. Model 6702	195 millicuries

13. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Brian Costleigh, M.D.	35.300; 35.400
Michael Ramjattansingh, M.D.	35.100; 35.200
Andrejs Strauss, M.D.	35.400
Ellen Bahtiarian, M.D.	35.100; 35.200; 35.300
Frances Esposito, M.D.	35.100; 35.200; 35.300; 35.500
Andrew Dahlke, M.D.	35.100; 35.200
Jeffrey McCann, M.D.	35.100; 35.200
Norman H. Boyer, M.D.	35.100; 35.200
Habib Bolourchi, M.D.	35.200
Georges Abdul-Karim Dahr, M.D.	35.200
Rajinder Prasad, M.D.	35.200
Ramon Alberto Rosa, M.D.	35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-17792-01

Docket or Reference Number
03013331

Amendment No. 38

Authorized Users	Material and Use
Dennis Michael Flamini, D.O.	35.100; 35.200

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A.	Application received October 16, 2003	[ML033000116]
B.	Letter dated February 4, 2005	[ML050730144]
C.	Letter dated December 7, 2005	[ML053530368]
D.	Letter dated August 26, 2008	[ML082600555]
E.	Letter dated August 5, 2009	[ML092250478]
F.	Facsimile dated September 24, 2009	[ML092680131]
G.	Letter dated October 19, 2009	[ML093000113]
H.	Letter dated January 20, 2011, except shielding assessment	[ML110200525]
I.	Letter dated February 7, 2011	[ML110390314]
J.	Letter dated June 13, 2011	[ML111680107]

For the U.S. Nuclear Regulatory Commission

Date December 2, 2011

By ***Original signed by Tara L. Weidner***

Tara L. Weidner
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406